These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 24626484)

  • 1. Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer's disease (Review).
    Cai Z
    Mol Med Rep; 2014 May; 9(5):1533-41. PubMed ID: 24626484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review.
    Manzoor S; Hoda N
    Eur J Med Chem; 2020 Nov; 206():112787. PubMed ID: 32942081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Monoamine Oxidase Activity in Alzheimer's Disease: An Insight into the Therapeutic Potential of Inhibitors.
    Behl T; Kaur D; Sehgal A; Singh S; Sharma N; Zengin G; Andronie-Cioara FL; Toma MM; Bungau S; Bumbu AG
    Molecules; 2021 Jun; 26(12):. PubMed ID: 34207264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease.
    Zheng H; Amit T; Bar-Am O; Fridkin M; Youdim MB; Mandel SA
    J Alzheimers Dis; 2012; 30(1):1-16. PubMed ID: 22387411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropep-1 ameliorates learning and memory deficits in an Alzheimer's disease mouse model, increases brain-derived neurotrophic factor expression in the brain, and causes reduction of amyloid beta plaques.
    Shin MK; Kim HG; Baek SH; Jung WR; Park DI; Park JS; Jo DG; Kim KL
    Neurobiol Aging; 2014 May; 35(5):990-1001. PubMed ID: 24268884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoamine oxidase-B inhibition in Alzheimer's disease.
    Riederer P; Danielczyk W; Grünblatt E
    Neurotoxicology; 2004 Jan; 25(1-2):271-7. PubMed ID: 14697902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β-amyloid in ageing and Alzheimer's disease.
    Weinreb O; Amit T; Bar-Am O; Youdim MB
    Br J Pharmacol; 2016 Jul; 173(13):2080-94. PubMed ID: 26332830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.
    Hardy J; Selkoe DJ
    Science; 2002 Jul; 297(5580):353-6. PubMed ID: 12130773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fyn, a potential target for Alzheimer's disease.
    Yang K; Belrose J; Trepanier CH; Lei G; Jackson MF; MacDonald JF
    J Alzheimers Dis; 2011; 27(2):243-52. PubMed ID: 21799250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review on cholinesterase inhibitors for Alzheimer's disease.
    Anand P; Singh B
    Arch Pharm Res; 2013 Apr; 36(4):375-99. PubMed ID: 23435942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caspase-6 as a novel early target in the treatment of Alzheimer's disease.
    LeBlanc AC
    Eur J Neurosci; 2013 Jun; 37(12):2005-18. PubMed ID: 23773070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's disease and amyloid: culprit or coincidence?
    Skaper SD
    Int Rev Neurobiol; 2012; 102():277-316. PubMed ID: 22748834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor.
    Weinreb O; Amit T; Bar-Am O; Youdim MB
    Int Rev Neurobiol; 2011; 100():191-215. PubMed ID: 21971009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer's disease.
    Kennedy BP; Ziegler MG; Alford M; Hansen LA; Thal LJ; Masliah E
    J Neural Transm (Vienna); 2003 Jul; 110(7):789-801. PubMed ID: 12811639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel chelators targeting cell cycle arrest, acetylcholinesterase, and monoamine oxidase for Alzheimer's therapy.
    Zheng H; Fridkin M; Youdim MB
    Curr Drug Targets; 2012 Jul; 13(8):1089-106. PubMed ID: 22676912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain prolyl oligopeptidase activity is associated with neuronal damage rather than beta-amyloid accumulation.
    Laitinen KS; van Groen T; Tanila H; Venäläinen J; Männistö PT; Alafuzoff I
    Neuroreport; 2001 Oct; 12(15):3309-12. PubMed ID: 11711876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer's disease.
    Patil PO; Bari SB; Firke SD; Deshmukh PK; Donda ST; Patil DA
    Bioorg Med Chem; 2013 May; 21(9):2434-50. PubMed ID: 23517722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.